Breaking Boundaries: SpringWorks Therapeutics Unveils New Findings from Phase 3 DEFI Trial of Nirogacestat for Desmoid Tumors at 2023 ASCO Annual Meeting
SpringWorks Therapeutics Announces New Data for Nirogacestat Treatment Nirogacestat Treatment Shows Promising Results SpringWorks Therapeutics, a biopharmaceutical company, recently revealed new data on the effectiveness of Nirogacestat treatment in reducing pain compared to a placebo. The study demonstrated rapid, sustained, and consistent reductions in pain using multiple assessment tools, providing hope for patients suffering from…